Welcome!

News Feed Item

Anaphore Announces Name Change to RuiYi and New Additions to Shanghai Management Team

Moves underscore company focus on the discovery and development of novel biologic therapies in China

LA JOLLA, Calif. and SHANGHAI, Oct. 4, 2012 /PRNewswire/ -- Anaphore announced today that its corporate name has changed to RuiYi.  As part of the company's shift in strategy to the discovery and development of novel biologic therapies in China, including monoclonal antibodies that target G protein coupled receptors (GPCRs), RuiYi has also added three seasoned leaders to its management team in Shanghai.

"RuiYi's new direction will enable us to focus on building our capabilities in Shanghai as we collaborate with a number of innovative drug discovery and development companies to advance our technology," commented Paul Grayson, President and CEO of RuiYi.

New RuiYi Drug Discovery Team

RuiYi also announced today that it has added three key members to its management team to guide its GPCR drug discovery efforts.  Chris Song, Ph.D., joins as Director of Operations, Shouhua (Josh) Xiao, Ph.D., joins as Senior Director of Protein Technology and Lei Shi, Ph.D., joins as Director of Antibody Discovery.

"Chris, Josh and Lei are all exceptionally talented individuals with extensive industry experience that is essential as we continue building a truly outstanding biologics drug discovery company in Shanghai," commented Anke Kretz-Rommel, Ph.D., Vice President of Research and Development, RuiYi.

Dr. Song has more than 20 years of experience in biomedical research and business. Prior to joining RuiYi, he led marketing and sales efforts at OriGene Technologies for its China business initiative. Before OriGene, Chris was with Applied Biosystems China, driving business growth in the pharmaceutical/biotech sector. He also held the position of Business Development Manager at Novartis China, developing business strategy and leading licensing activities for the Oncology Business. Dr. Song received his M.B.A from Stephen M. Ross School of Business at the University of Michigan, his Ph.D. in Molecular Biology and Oncology from the University of Queensland, Australia and a B.Sc from Shandong University, China.

Dr. Xiao has worked in the biotech industry for over 14 years. Prior to joining RuiYi, he was Principal Scientist and led the biologics drug discovery efforts for Oncology at Amgen South San Francisco. Prior to Amgen, he managed the HTS/Molecular Pharmacology group at Tularik and previously worked at Millennium Pharmaceuticals. Dr. Xiao obtained his Ph.D. in Biochemistry from Louisiana State University and conducted his postdoctoral training with Dr. James Manley at Columbia University. He currently serves as Co-chair of the 2011-2012 EC Business & Career Development Committee of the Chinese-American BioPharmaceutical Society.

Dr. Shi joins RuiYi from Centyrex, an internal venture of Johnson & Johnson, where he was responsible for library technology development and lead generation in the area of immunology and oncology. Prior to Centyrex, Dr. Shi was a Senior Research Scientist at Centocor R&D of Johnson and Johnson, where he led a project on developing and validating large scale de novo antibody library technology on a novel phage display platform and was the leading author on the publication and patent on this effort.  Before his career in the biopharmaceutical industry, Dr. Shi conducted his postdoctoral research on innate immunology at Harvard Medical School and Massachusetts General Hospital. He obtained his Ph.D. in Molecular Biology from University of Illinois at Chicago and an Executive Master's degree in Technology Management from the University of Pennsylvania and the Wharton School of Business.

New RuiYi Corporate Headquarters

RuiYi is moving its corporate offices to new space in La Jolla, CA.  Effective November 15, 2012, RuiYi's California-based office will be at:  505 Coast Blvd South, La Jolla, CA 92037.

About RuiYi

RuiYi is focused on the discovery and development of novel biologic therapies in China, including monoclonal antibodies that target G protein coupled receptors (GPCRs).  RuiYi's executive management team has offices in La Jolla, California while all of RuiYi's discovery efforts are located in Shanghai, China.  RuiYi's research facility is located in the Zhangjiang Hi-Tech Park in Pudong Shanghai, China.

For more information please visit www.ruiyibio.com.

SOURCE RuiYi

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
With more than 30 Kubernetes solutions in the marketplace, it's tempting to think Kubernetes and the vendor ecosystem has solved the problem of operationalizing containers at scale or of automatically managing the elasticity of the underlying infrastructure that these solutions need to be truly scalable. Far from it. There are at least six major pain points that companies experience when they try to deploy and run Kubernetes in their complex environments. In this presentation, the speaker will d...
While DevOps most critically and famously fosters collaboration, communication, and integration through cultural change, culture is more of an output than an input. In order to actively drive cultural evolution, organizations must make substantial organizational and process changes, and adopt new technologies, to encourage a DevOps culture. Moderated by Andi Mann, panelists discussed how to balance these three pillars of DevOps, where to focus attention (and resources), where organizations might...
The deluge of IoT sensor data collected from connected devices and the powerful AI required to make that data actionable are giving rise to a hybrid ecosystem in which cloud, on-prem and edge processes become interweaved. Attendees will learn how emerging composable infrastructure solutions deliver the adaptive architecture needed to manage this new data reality. Machine learning algorithms can better anticipate data storms and automate resources to support surges, including fully scalable GPU-c...
When building large, cloud-based applications that operate at a high scale, it's important to maintain a high availability and resilience to failures. In order to do that, you must be tolerant of failures, even in light of failures in other areas of your application. "Fly two mistakes high" is an old adage in the radio control airplane hobby. It means, fly high enough so that if you make a mistake, you can continue flying with room to still make mistakes. In his session at 18th Cloud Expo, Le...
Machine learning has taken residence at our cities' cores and now we can finally have "smart cities." Cities are a collection of buildings made to provide the structure and safety necessary for people to function, create and survive. Buildings are a pool of ever-changing performance data from large automated systems such as heating and cooling to the people that live and work within them. Through machine learning, buildings can optimize performance, reduce costs, and improve occupant comfort by ...
As Cybric's Chief Technology Officer, Mike D. Kail is responsible for the strategic vision and technical direction of the platform. Prior to founding Cybric, Mike was Yahoo's CIO and SVP of Infrastructure, where he led the IT and Data Center functions for the company. He has more than 24 years of IT Operations experience with a focus on highly-scalable architectures.
The explosion of new web/cloud/IoT-based applications and the data they generate are transforming our world right before our eyes. In this rush to adopt these new technologies, organizations are often ignoring fundamental questions concerning who owns the data and failing to ask for permission to conduct invasive surveillance of their customers. Organizations that are not transparent about how their systems gather data telemetry without offering shared data ownership risk product rejection, regu...
CI/CD is conceptually straightforward, yet often technically intricate to implement since it requires time and opportunities to develop intimate understanding on not only DevOps processes and operations, but likely product integrations with multiple platforms. This session intends to bridge the gap by offering an intense learning experience while witnessing the processes and operations to build from zero to a simple, yet functional CI/CD pipeline integrated with Jenkins, Github, Docker and Azure...
René Bostic is the Technical VP of the IBM Cloud Unit in North America. Enjoying her career with IBM during the modern millennial technological era, she is an expert in cloud computing, DevOps and emerging cloud technologies such as Blockchain. Her strengths and core competencies include a proven record of accomplishments in consensus building at all levels to assess, plan, and implement enterprise and cloud computing solutions. René is a member of the Society of Women Engineers (SWE) and a m...
Dhiraj Sehgal works in Delphix's product and solution organization. His focus has been DevOps, DataOps, private cloud and datacenters customers, technologies and products. He has wealth of experience in cloud focused and virtualized technologies ranging from compute, networking to storage. He has spoken at Cloud Expo for last 3 years now in New York and Santa Clara.
Enterprises are striving to become digital businesses for differentiated innovation and customer-centricity. Traditionally, they focused on digitizing processes and paper workflow. To be a disruptor and compete against new players, they need to gain insight into business data and innovate at scale. Cloud and cognitive technologies can help them leverage hidden data in SAP/ERP systems to fuel their businesses to accelerate digital transformation success.
Containers and Kubernetes allow for code portability across on-premise VMs, bare metal, or multiple cloud provider environments. Yet, despite this portability promise, developers may include configuration and application definitions that constrain or even eliminate application portability. In this session we'll describe best practices for "configuration as code" in a Kubernetes environment. We will demonstrate how a properly constructed containerized app can be deployed to both Amazon and Azure ...
Poor data quality and analytics drive down business value. In fact, Gartner estimated that the average financial impact of poor data quality on organizations is $9.7 million per year. But bad data is much more than a cost center. By eroding trust in information, analytics and the business decisions based on these, it is a serious impediment to digital transformation.
Digital Transformation: Preparing Cloud & IoT Security for the Age of Artificial Intelligence. As automation and artificial intelligence (AI) power solution development and delivery, many businesses need to build backend cloud capabilities. Well-poised organizations, marketing smart devices with AI and BlockChain capabilities prepare to refine compliance and regulatory capabilities in 2018. Volumes of health, financial, technical and privacy data, along with tightening compliance requirements by...
Predicting the future has never been more challenging - not because of the lack of data but because of the flood of ungoverned and risk laden information. Microsoft states that 2.5 exabytes of data are created every day. Expectations and reliance on data are being pushed to the limits, as demands around hybrid options continue to grow.